223 related articles for article (PubMed ID: 38169045)
1. [Immunotherapy against gliomas].
Sahm K; Weiss T
Nervenarzt; 2024 Feb; 95(2):111-116. PubMed ID: 38169045
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
3. Dendritic-cell- and peptide-based vaccination strategies for glioma.
Yamanaka R
Neurosurg Rev; 2009 Jul; 32(3):265-73; discussion 273. PubMed ID: 19214609
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
5. Peptide-based immunotherapeutic approaches to glioma: a review.
Yamanaka R; Itoh K
Expert Opin Biol Ther; 2007 May; 7(5):645-9. PubMed ID: 17477802
[TBL] [Abstract][Full Text] [Related]
6. Current Immunotherapeutic Approaches for Malignant Gliomas.
Han MH; Kim CH
Brain Tumor Res Treat; 2022 Jan; 10(1):1-11. PubMed ID: 35118842
[TBL] [Abstract][Full Text] [Related]
7. The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas.
Li G; Mitra S; Wong AJ
Neurosurg Clin N Am; 2010 Jan; 21(1):87-93. PubMed ID: 19944969
[TBL] [Abstract][Full Text] [Related]
8. Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy.
Mishchenko TA; Turubanova VD; Gorshkova EN; Krysko O; Vedunova MV; Krysko DV
Front Immunol; 2023; 14():1299064. PubMed ID: 38274827
[TBL] [Abstract][Full Text] [Related]
9. [Peptide vaccination therapy for malignant glioma].
Yamanaka R; Itoh K
Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell immunotherapy for malignant gliomas.
Luptrawan A; Liu G; Yu JS
Rev Recent Clin Trials; 2008 Jan; 3(1):10-21. PubMed ID: 18474011
[TBL] [Abstract][Full Text] [Related]
11. The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.
Maxwell R; Luksik AS; Garzon-Muvdi T; Lim M
Curr Neurol Neurosci Rep; 2017 Jun; 17(6):50. PubMed ID: 28488122
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH
Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045
[TBL] [Abstract][Full Text] [Related]
13. Research Progress in Immunotherapy of Gliomas.
Duan ZH; Wei ZL
J Integr Neurosci; 2023 Aug; 22(5):118. PubMed ID: 37735122
[TBL] [Abstract][Full Text] [Related]
14. T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches.
Akasaki Y; Black KL; Yu JS
Front Biosci; 2005 Sep; 10():2908-21. PubMed ID: 15970545
[TBL] [Abstract][Full Text] [Related]
15. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
Chonan M; Saito R; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Watanabe M; Kikuchi T; Ishii N; Tominaga T
Neuro Oncol; 2015 Nov; 17(11):1453-62. PubMed ID: 26008605
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic strategies for malignant glioma.
Fenstermaker RA; Ciesielski MJ
Cancer Control; 2004; 11(3):181-91. PubMed ID: 15153842
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Translational Advances in Glioma Immunotherapy.
Bunse L; Bunse T; Krämer C; Chih YC; Platten M
Neurotherapeutics; 2022 Oct; 19(6):1799-1817. PubMed ID: 36303101
[TBL] [Abstract][Full Text] [Related]
18. Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.
Wang JY; Bettegowda C
J Neurooncol; 2015 Jul; 123(3):373-83. PubMed ID: 25697584
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of the glioma microenvironment].
Herrlinger U; Platten M
Nervenarzt; 2015 Jun; 86(6):684, 686-8, 690-1. PubMed ID: 25962344
[TBL] [Abstract][Full Text] [Related]
20. Exploitation of immune mechanisms in the treatment of central nervous system cancer.
Pollack IF; Okada H; Chambers WH
Semin Pediatr Neurol; 2000 Jun; 7(2):131-43. PubMed ID: 10914414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]